Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma
Sponsor: Regeneron Pharmaceuticals
Listed as NCT05097287, this observational or N/A phase trial focuses on Asthma and remains ongoing. Sponsored by Regeneron Pharmaceuticals, it has been updated 38 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
38 versions recorded-
Apr 17, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE4 → None
-
Mar 2026 — Apr 2026 [monthly]
Recruiting PHASE4
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE4
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE4
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE4
▶ Show 33 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE4
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE4
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE4
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE4
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE4
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE4
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE4
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE4
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE4
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE4
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE4
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE4
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE4
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE4
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE4
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE4
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE4
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE4
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE4
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE4
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE4
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE4
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE4
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE4
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE4
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .